Is the revised International staging system for myeloma valid in a real world population?
Ieuan Walker(King's College London), Matthew Streetly(King's College - North Carolina), Steve Schey(King's College London), Darius Ladon(King's College Hospital), Inas El‐Najjar(Guy's and St Thomas' NHS Foundation Trust), Alice Coady(King's College London), Michael Neat(Guy's Hospital), Majid Kazmi, Reuben Benjamin(King's College London)
Cited by 13
Related Papers
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
|Blood|2023|330
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315